SHA24/041002

Roberto Ferrari Disclosures Speaker’s bureau:

Servier, Bayer, Roche Boehringer Ingelheim

Research grant:

Servier, Novartis, Roche Boehringer Ingelheim,

Advisory Board:

Servier, Bayer, Roche Boehringer Ingelheim

Chronic Cardiovascular Disease Registry

•Promoted by the ESC •Conducted by the ESC, EAPCI and WG on Peripheral Circulation

Why?

Background •CVD is the first cause of

mortality despite modern treatment and prevention measures

•Most recent epidemiological data were released in 2008

Background •Epidemiology has changed with aging and improved prognosis

•West to East gradient of CVD

prevalence and mortality exists

•This is inversely related to per

capita and gross national product

CVD death rates 1994 - 2004

%

Finland

UK

Albania

Ukraine

Background •Atherosclerosis is a systemic disease

•CVD is often associated with- Cerobrovascular disease - Lower extremity artery disease (LEAD)

Background • Stroke mortality ranges from

10% to 30%, morbidity is high

• LEAD increase from 3% to 20% with aging

But

•Data on presentation and

management of CVD and PAD come from clinical trials or registries focusing on specific manifestations of the disease

•There are no European

contemporary data reflecting daily practice of this epidemic

ESC CVD Registry will provide a picture of:

•CV atherosclerosis •Its risk factor •Its clinical implication •Its treatment (preventative and therapeutic)

Registry: questions •What are the demographics and clinical profiles of the CVD and PAD population?

•What is the current daily treatment?

•Is there adherence to Guidelines and evidence-based practice?

Registry: questions •What are the changes during follow-up?

•What are the geographic

variations in management?

•What are the determinants of long-term prognosis?

ESC CVD Registry: 4 cohorts 1

•Consecutive P with CAD

undergoing urgent PCI for NSTE ACS -Enrolment: cath lab

2

•Consecutive P undergoing

elective PCI for stable angina -Enrolment: cath lab

ESC CVD Registry: 4 cohorts

•

3 Consecutive P with PAD (carotid

•

or limb) undergoing interventions -Enrolment: cath lab -Ancillary study: diabetic foot

4 Consecutive P with stable CAD

-Enrolment: general hospital

ESC CVD Registry: methods

•Enrolment: 1 day per week for 6 months

•Follow-up:

1 visit at 6 months

National and European Networks

•Cohort 1: 1 centre per 2 million

1

inhabitants. (10 centres / country, ranging 5-10 / country)

2

•Cohort 2: 1 centre per 2 million

inhabitants. (10 centres / country, ranging 5-10 / country)

National and European Networks

•

3 Cohort 3: all centres performing

more than 30 peripheral procedures per year per country (5-10 centres / country) 4

•Cohort 4: 15-30 general hospitals or clinics (no interventional or surgical facilities)

Participating countries •Northern •Eastern Lithuania Norway

•Southern Turkey Portugal Italy Greece

Russia Romania Bulgaria Poland

•Central

France Germany Netherlands

Cohort 1*

Cohort 2*

Cohort 3**

Cohort 4***

CAD with NSTE-ACS Urgently revascularised

Chronic CAD Electively revascularised

PAD All revascularised

Chronic CAD Non revascularised

20 P per centre

10 P per centre

10 P per centre

20 P per centre

2600 patients

1300 patients

910 patients

3900 patients

Total population 8711 patients * 10 centres per country per 13 countries ** 7 centres per country per 13 countries *** 15 centres per country per 13 countries

ESC CVD Registry: design

•General observational registry

•Pilot phase

(1 year, 13 countries)

•Long term longitudinal

ESC CVD Registry: structure •Executive Committee Roberto Ferrari (Chairman, Exec Comm) Michel Komajda(Chairman, Steering Comm) Francesco Cosentino Gabriel Steg Aldo Maggioni Marco Valgimigli Luigi Tavazzi Franz Weidinger

•Steering Committee

Each national coordinator indicated by National Society President

ESC CVD Registry: organisation

•EORP team based at HH •Database collected and analysed at HH

•Progress published on a protected website with

ESC CVD Registry: timing • Centre selection • Regulatory procedures • FPFV • LP enrolment • LPLV • Database locked • Final result presentation

Oct-Nov 2012 Nov 2012-Jan 2013 Feb 2013 Oct 2013 April 2014 June 2014 ESC Congress 2014